Gaucher disease
- PMID: 23622393
- DOI: 10.1016/B978-0-444-59565-2.00040-X
Gaucher disease
Abstract
Gaucher disease is an autosomal recessive condition due to glucocerebrosidase deficiency responsible for the lysosomal accumulation of glucosylceramide, a complex lipid derived from cell membranes, mainly in macrophages. It is due to mutations mostly in the GBA gene, although saposine C deficiency is due to mutations in the PSAP gene. It encompasses an extremely heterogeneous spectrum of clinical involvement from the fetus to adulthood. Splenomegaly, blood cytopenia, and bone involvement are the main manifestations of Gaucher disease, but nervous system degeneration is observed in about 5-10% of patients. The accumulation in neurons of glucosylceramide and its derivative, psychosine, are thought to underlie neuronal dysfunction and death, although Gaucher cells that mostly accumulate such substances are mainly macrophages. Enzyme replacement therapy dramatically improves the outcome of patients because of its extreme efficacy in the treatment of the systemic involvement. However, it has only limited effects on most neurological signs.
Copyright © 2013 Elsevier B.V. All rights reserved.
Similar articles
-
Enzyme Replacement Therapy in a Gaucher Family.J Natl Med Assoc. 2018 Aug;110(4):330-333. doi: 10.1016/j.jnma.2017.06.013. Epub 2017 Jul 14. J Natl Med Assoc. 2018. PMID: 30126557
-
[Gaucher disease: A review].Rev Med Interne. 2019 May;40(5):313-322. doi: 10.1016/j.revmed.2018.11.012. Epub 2019 Jan 11. Rev Med Interne. 2019. PMID: 30638965 Review. French.
-
Gaucher Disease: Clinical, Biological and Therapeutic Aspects.Pathobiology. 2016;83(1):13-23. doi: 10.1159/000440865. Epub 2015 Nov 21. Pathobiology. 2016. PMID: 26588331 Review.
-
Ambroxol improves skeletal and hematological manifestations on a child with Gaucher disease.J Hum Genet. 2020 Mar;65(3):345-349. doi: 10.1038/s10038-019-0704-3. Epub 2019 Dec 11. J Hum Genet. 2020. PMID: 31822786
-
Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response.Blood. 2011 Oct 20;118(16):e118-27. doi: 10.1182/blood-2011-05-352971. Epub 2011 Aug 25. Blood. 2011. PMID: 21868580 Free PMC article.
Cited by
-
Advances in AAV-mediated gene replacement therapy for pediatric monogenic neurological disorders.Mol Ther Methods Clin Dev. 2024 Oct 16;32(4):101357. doi: 10.1016/j.omtm.2024.101357. eCollection 2024 Dec 12. Mol Ther Methods Clin Dev. 2024. PMID: 39559557 Free PMC article. Review.
-
TALEN-mediated intron editing of HSPCs enables transgene expression restricted to the myeloid lineage.Mol Ther. 2024 Jun 5;32(6):1643-1657. doi: 10.1016/j.ymthe.2024.04.001. Epub 2024 Apr 6. Mol Ther. 2024. PMID: 38582963 Free PMC article.
-
Precision Medicine in Parkinson's Disease: From Genetic Risk Signals to Personalized Therapy.Brain Sci. 2022 Sep 28;12(10):1308. doi: 10.3390/brainsci12101308. Brain Sci. 2022. PMID: 36291241 Free PMC article. Review.
-
mTOR hyperactivity mediates lysosomal dysfunction in Gaucher's disease iPSC-neuronal cells.Dis Model Mech. 2019 Oct 16;12(10):dmm038596. doi: 10.1242/dmm.038596. Dis Model Mech. 2019. PMID: 31519738 Free PMC article.
-
Parkinson's disease in Gaucher disease patients: what's changing in the counseling and management of patients and their relatives?Orphanet J Rare Dis. 2020 Sep 23;15(1):262. doi: 10.1186/s13023-020-01529-y. Orphanet J Rare Dis. 2020. PMID: 32967694 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous